Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 June;59(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 June;59(2):168-83

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413


eTOC

 

REVIEWS  25 YEARS OF IMMUNOSCINTIGRAPHY AND THERAPY WITH IRIST


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 June;59(2):168-83

Copyright © 2015 EDIZIONI MINERVA MEDICA

lingua: Inglese

New approaches for imaging and therapy of solid cancer

Sollini M. 1, Boni R. 2, Traino A. C. 3, Lazzeri E. 2, Pasqualetti F. 4, Modeo L. 2, Mariani G. 2, Petrini M. 5, Erba P. A. 2

1 Nuclear Medicine Unit, Department of Oncology and Advanced Technology, Arcispedale Santa Maria Nuova, IRCCS, Reggio Emilia, Italy;
2 Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, Italy;
3 Medical Physics Unit, Azienda Ospedaliero‑Universitaria Pisana, Pisa, Italy;
4 Radiotherapy Unit, Azienda Ospedaliero‑Universitaria Pisana, Pisa, Italy;
5 Department of Haematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy


PDF  


Radionuclide therapy is a systemic treatment that aims to deliver cytotoxic radiation to cancer cells. Due to their properties, antibodies have been considered as suitable agent for the delivery of therapeutic radioisotopes, radioimmunotherapy (RIT). This article gives an overview of new approaches for imaging and therapy of solid cancer with particular attention to strategies to enhance treatment success. Examples of increased antibody uptake by targeting stromal constituent of tumor microenvironment such as fibronectin (FN) an important tumor-associated angiogenesis targeting agent, with specifically designed antibody format will be provided. Strategies oriented to identify patients most likely to benefit from RIT including identification of radiosensitivity profiles, in vivo target identification by teragnostic approach and better prediction of dosimetric estimates would be presents. Combination regimens such as with chemo-radiotherapy and immunotherapy would be also discussed as an approach to enhance RIT success.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

paola.erba@unipi.it